top of page
Browse by category
Search
MBX Biosciences announces positive phase 1 topline results for MBX 1416 for the treatment of PBH
MBX Biosciences has announced positive results from its Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical...
Clinical trial of MBX 1416 for Post-Bariatric Hypoglycemia begins
The first participant has been dosed in MBX Biosciences’ Phase 1/2 clinical trial of MBX 1416, the company’s long-acting glucagon-like...
MBX Biosciences gains FDA clearance to study MBX 1416 for post-bariatric hypoglycaemia
MBX Biosciences, a clinical stage biopharmaceutical company developing Precision Endocrine Peptide (PEP) therapeutics to treat an array...
Browse by tag
bottom of page